IDO1 inhibitors were developed and tested in numerous cancer clinical settings without knowledge of the overlapping pathways regulated by IL4i1, and without knowing that both IDO1 and IL4i1 control redox stress responses. The gene discussed is IL4I1; the disease is cancer.